Document is current
Any future updates will be listed below
-
Authors
Leonardi, Andrea https://orcid.org/0000-0002-7246-8580
Aragona, Pasquale
Sainz de la Maza, Maite
Seleznev, Aleksei
Wylegala, Edward
Villani, Edoardo
Baudouin, Christophe
,
Liehneova, Ivana
Korda, Vladimir
Nekolova, Jana
Masek, Petr
Cech, Ales
Rybarova, Daniela
Laboha, Tatana
Fogagnolo, Paolo
Barabino, Stefano
Viola, Francesco
Siewierska, Malgorzata
Zarnowski, Tomasz
Mrukwa-Kominek, Ewa
Fryczkowski, Piotr
Misiuk-Hojlo, Marta
Astakhov, Sergey
Gavrilova, Natalya
Gornostaeva, Ekaterina
Seleznev, Aleksei
Pozdeeva, Nadezhda
Vargas, Arturo Ruiz
Peris-Martinez, Cristina
Mendicute, Javier
Montero, Jesus
Lozano, Isabel Pinilla
Mateu, Jose Lamarca
Alptekin, Banu Bozkurt
Gunduz, Omur
Palamar, Melis
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04144413 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis
https://doi.org/10.1007/s40123-026-01411-3
-
Funding
Funding for this research was provided by:
Santen
- License Information
-
More Information
Article History
Received: 13 March 2026
Accepted: 15 May 2026
First Online: 12 June 2026
Change Date: 1 August 2026
Change Type: Update
Change Details: The original online version of this article was revised due to authors affiliations are incorrectly incorporated in the acknowledgment section. Now, it have been corrected.
Declarations
Conflict of Interest: Andrea Leonardi is a consultant for or has received speaker fees from AstraZeneca, Bausch & Lomb, Dompè, FAES Farma, FIDIA, Novartis, Santen Pharmaceutical Co. Ltd., Laboratoires Théa, and SIFI. Pasquale Aragona received honoraria from Abbvie, Alcon, Bausch & Lomb, FB Vision, Fidia, Medivis, Santen, Sifi, Sun Pharma, Tarsus, Thea, and TRB Chemedica for participating in advisory boards, educational events, focus groups and/or expert panels, and scientific research support given to his department. Maite Sainz de la Maza received honoraria from Santen, Thea, Bausch & Lomb, NTC, Sanofi, and Novartis for participating in advisory boards, educational events, focus groups,and/or expert panels, and scientific research support. Aleksei Seleznev received honoraria from Sentiss Rus, Santen, Thea, NTC, Novartis, AbbVie, and Viatris for participating in advisory boards, educational events, focus groups and/or expert panels, and scientific research support. Edward Wylegala is a consultant for Bausch & Lomb, Santen, Fidia, and Théa. Edoardo Villani has received honoraria from AbbVie, Alcon, Bausch & Lomb, Diadema, Essilor Luxottica, FB Vision, Fidia, Santen, Sifi, Thea, Unifarco, and Visufarma for contributing to advisory boards, educational events, and focus groups and/or expert panels. Christophe Baudouin is a consultant for Bausch & Lomb, Horus Pharma, Oculis, Santen, Glaukos, and Théa.
Ethical Approval: The study was performed after independent ethics committee (IEC) approval. The protocol and amendments were reviewed and approved by the relevant IECs for each study site. Participating patients were required to give written informed consent. The study was conducted in accordance with the Declaration of Helsinki and its most recent update and the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) guideline.
